Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH

What happened: Liquidia entered a global settlement with United Therapeutics resolving all six pending lawsuits. YUTREPIA will remain available to PAH patients without disruption, and Liquidia agreed not to appeal the Delaware court ruling on the '327 patent. Key numbers: Net Why it matters: The settlement ends years of litigation and gives Liquidia certainty to focus on growing YUTREPIA. Liquidia removed the PH-ILD indication from the label and will no longer promote it for PH-ILD. Management expects to fund payments from YUTREPIA sales and cash on hand without additional financing. Market: +26.6% by next close ($33.94 on Oct 14), +8.1% YTD

Liquidia entered a global settlement with United Therapeutics resolving all six pending lawsuits. YUTREPIA will remain available to PAH patients without disruption, and Liquidia agreed not to appeal the Delaware court ruling on the '327 patent.

The settlement ends years of litigation and gives Liquidia certainty to focus on growing YUTREPIA. Liquidia removed the PH-ILD indication from the label and will no longer promote it for PH-ILD. Management expects to fund payments from YUTREPIA sales and cash on hand without additional financing. Market: +26.6% by next close ($33.94 on Oct 14), +8.1% YTD